Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Telomir Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Telomir Pharmaceuticals, Inc.

TELO

Telomir Pharmaceuticals, Inc.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals develops innovative small molecule therapies targeting cellular metal imbalances, oxidative stress, and telomere maintenance. Its lead candidate, Telomir-1, aims to treat age-related diseases, rare genetic disorders like Wilson’s disease and Progeria, metabolic conditions such as Type 2 diabetes, and viral infections. The company focuses on preclinical research, regulatory approval, and potential market expansion in aging, neurodegeneration, and chronic diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Telomir Pharmaceuticals, Inc.

1
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports Q1 2026 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports $10.4 Million Net Loss for Fiscal Year 2025, Plans Merger with TELI Pharmaceuticals

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports Reduced Losses and Increased Assets in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports $5.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports $2.18 Million Net Loss in Q1 2025, Focuses on Research and Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports $16.5 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals Reports Significant Financial Changes, Net Loss, and Doubt Over Going Concern in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments